733
edits
ICD Primary prevention trials: Difference between revisions
no edit summary
Secretariat (talk | contribs) No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
! Main Finding | ! Main Finding | ||
|- | |- | ||
| MADIT I<cite>35</cite> | | '''MADIT I'''<cite>35</cite> | ||
| Prior MI, EF ≤35%, NSVT, inducible and nonsuppressible VT on EPS, NYHA class I–III | | Prior MI, EF ≤35%, NSVT, inducible and nonsuppressible VT on EPS, NYHA class I–III | ||
| align="center" | 196 | | align="center" | 196 | ||
| Line 20: | Line 20: | ||
mortality with ICD (''P''=0.009); absolute RR 23% | mortality with ICD (''P''=0.009); absolute RR 23% | ||
|- | |- | ||
| CABG-PATCH<cite>36</cite> | | '''CABG-PATCH'''<cite>36</cite> | ||
| EF <35%, abnormal SAECG, elective CABG | | EF <35%, abnormal SAECG, elective CABG | ||
| align="center" | 900 | | align="center" | 900 | ||
| Line 28: | Line 28: | ||
|- | |- | ||
! '''MUSTT'''<cite>37</cite> | |||
| Prior MI, EF ≤40%, NSVT, inducible VT on EPS | | Prior MI, EF ≤40%, NSVT, inducible VT on EPS | ||
| align="center" | 704 | | align="center" | 704 | ||
| Line 36: | Line 36: | ||
|- | |- | ||
| MADIT II<cite>39</cite> | | '''MADIT II'''<cite>39</cite> | ||
| Prior MI≤1 month, EF≤30%, NYHA class I–III | | Prior MI≤1 month, EF≤30%, NYHA class I–III | ||
| align="center" | 1232 | | align="center" | 1232 | ||
| Line 44: | Line 44: | ||
|- | |- | ||
| DINAMIT<cite>38</cite> | | '''DINAMIT'''<cite>38</cite> | ||
| Recent (6–40 days) MI, EF≤35%, abnormal HRV or elevated average HR on 24-h Holter, NYHA class I–III | | Recent (6–40 days) MI, EF≤35%, abnormal HRV or elevated average HR on 24-h Holter, NYHA class I–III | ||
| align="center" | 674 | | align="center" | 674 | ||
| Line 52: | Line 52: | ||
|- | |- | ||
| SCD-HeFT<cite>34</cite> | | '''SCD-HeFT'''<cite>34</cite> | ||
| EF≤35%, (ischemic or nonischemic) NYHA class II–III | | EF≤35%, (ischemic or nonischemic) NYHA class II–III | ||
| align="center" | 2521 | | align="center" | 2521 | ||